Therefore, when treating patients with low expression levels or diminished activity of topoisomerase 1, TOP1-ADC might not have sufficient therapeutic efficacy, even when the conjugate is successfully targeted to the cancer cell. The gene discussed is TOP1; the disease is cancer.